02 October 2020
Paradigm Biopharmaceuticals Pty Ltd has announced they will be conducting the Phase 1/2 trial at Women’s and Children’s Hospital, Adelaide. The Principal investigator is Dr David Ketteridge.Read More
22 March 2020
The MPS Society has developed this advice in conjunction with our expert Medical team.Read More
27 January 2020
Families, clinical and scientific leaders will join together over dinner during the National MPS conference at Glenelg South Australia to discuss Rare Disease Advocacy. The theme of the meeting "Our Future and Hope" inspires the champions of rare disease with the mission to find a cure for MPS and Related Diseases.
14 March 2019
These are steady steps towards development of JR-141 as a treatment option for Hunter patients around the globe.
07 February 2019
Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases
15 October 2018
The Department of health has recently completed the LSDP Program review. This review of the LSDP has refined how new medicines are approved and current medicines are reviewed. There are now more definitive timelines for approvals to be given for medications to be admitted to the LSDP.Read More
06 September 2018
2ND ASIA PACIFIC LYSOSOMAL CONFERENCE 2019
The LDNZ Trustees are thrilled to bring our 2nd Asia Pacific Lysosomal Conference to Auckland.
Date: 14th–16th February 2019
Where: Airport Holiday Inn
We are very pleased to announce that Prof. David Palmer has agreed to be the Scientific Chair. Prof. Palmer's vision for the meeting is:
On behalf of Lysosomal Diseases New Zealand and the Scientific Committee we look forward to welcoming you all to the 2nd Asia-Pacific Lysosomal Conference to be held in New Zealand.
This special meeting brings together scientists, clinicians, carers and families affected by these devastating diseases in a unique format, to discuss the latest advancements in treatments, therapies and management of these very complex conditions, with the intent to stimulate an interchange of ideas and develop collaborations among the investigators with different approaches and expertise.
There will be presentations on the current state of knowledge of these diseases and workshops for families and affected patients which are designed to foster interaction between investigators and families and to build networks within the Asia Pacific Region.
David Palmer - Scientific Chair
We look forward to welcoming you all to Auckland, New Zealand.
06 September 2018
• Novel, one-time, investigational gene therapy treatment for MPS IIIA focused toward preventing neurocognitive decline • LYS-SAF302 product manufacture released to support the demands of phase 2-3 clinical trial • Implementation of the clinical trial depends on the strengthening of the Company’s financial capabilities, which is currently being pursued